Novo Nordisk arrived at the American Diabetes Association’s annual meeting in New Orleans armed with a flood of fresh clinical evidence, yet the company’s shares remain stuck in a deep rut. The stock closed Friday at €37.27, roughly 10% below its 200-day moving average of €41.66 and more than 40% lower than a year ago. With an investor webcast scheduled for Sunday evening, the question is whether the data parade can finally turn the tide — or whether the market’s scepticism runs too deep.
Semaglutid Shows Its Mettle in a Real-World Head-to-Head
One of the most compelling studies unveiled at the congress is COMPETE SWITCH, a large analysis drawn from a US claims database covering January 2018 to September 2025. Novo Nordisk examined what happens when Type-2 diabetes patients on Semaglutide 1 mg either raise the dose to 2 mg or switch to Eli Lilly’s Tirzepatide. With nearly 55,550 patients in the up‑titration group, 74.7% achieved an HbA1c below 7% after one year, versus 75.1% of those who moved to Tirzepatide — a statistical dead heat. The real surprise came in weight loss: 60.5% of the Semaglutide 2 mg cohort shed at least 5% of their body weight, compared with 55.3% for Tirzepatide.
Novo Nordisk is quick to note the study’s limits — it relies on billing data, not a controlled trial, so causation cannot be inferred. Still, the numbers give doctors a reason to think twice before switching patients away from Semaglutide, especially as Tirzepatide has been eating into Novo’s market share.
Beyond Diabetes: Sleep Apnea, Asthma, and a Broad Pipeline
Post‑hoc analyses from the SELECT programme added further heft. Semaglutide 2.4 mg reduced the risk of developing obstructive sleep apnoea by 52% (30 events vs. 65 on placebo; hazard ratio 0.48). In a separate SELECT sub‑analysis of patients with cardiovascular disease and overweight, asthma‑related events fell to 27 versus 46 in the control group (hazard ratio 0.58).
Novo also rolled out Phase‑3 data for CagriSema, its fixed‑dose combination of Semaglutide and the amylin analogue Cagrilintide, from the REIMAGINE‑1‑to‑3 trials targeting blood glucose control and weight loss in Type‑2 diabetes. The company submitted CagriSema for US approval in December 2025; a decision is expected in the fourth quarter of next year. Additional findings on IcoSema and Efruxifermin underlined the breadth of the pipeline.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
A Strategic Bet on Preserving Muscle
Away from the conference floor, Novo Nordisk struck a deal that addresses one of the thorniest issues in obesity treatment: the loss of lean mass during significant weight loss. On 2 June, Veru Inc. announced a clinical supply agreement with Novo for the Phase‑2b PLATEAU study. The double‑blind, placebo‑controlled trial will test Enobosarm in roughly 200 patients aged 65 and older with obesity who are also taking Semaglutide. Endpoints include body weight, muscle mass, bone density, and physical function.
Novo will supply Wegovy free of charge for the duration of the study. In return, it gains first negotiation rights on any future commercial opportunities from an Enobosarm‑GLP‑1 combination. The news gave the stock a four‑percent pop on the day — enough for a single‑session bounce, but far from a lasting recovery.
The Weight of Guidance and a Price Fix
Underpinning the share price weakness is the company’s own sobering outlook. Novo Nordisk now expects revenue and operating profit to decline by 4% to 12% in 2026 at constant exchange rates — a slight improvement from an earlier forecast of 5% to 13%. The first quarter already showed a 4% drop in adjusted sales, though the obesity franchise grew 22%, demonstrating that demand remains strong even as pricing pressure builds.
A new “Most Favoured Nations” agreement takes effect on 1 July 2026, broadening access to Wegovy and Ozempic under Medicare Part D, Medicaid, and direct patient copays. How that pricing framework hits second‑half sales will become clear when third‑quarter results land on 5 August. Meanwhile, the buyback programme continues: by the end of May, Novo had repurchased nearly 17.9 million B‑shares at an average price of DKK 263.47 apiece.
What to Watch Next
As the European markets open on Monday, investors will be parsing the Sunday webcast and the dozens of sub‑analyses from the SELECT, STEP, ESSENCE, and OASIS programmes. The stock is trading above its 50‑day moving average of €35.80 but well below the 200‑day line — a technical picture that suggests the bears still have the upper hand. For Novo Nordisk, the ADA data dump may provide enough fuel for a short‑term bounce, but a sustained turnaround will require more than a single conference’s worth of results.
Ad
Novo Nordisk Stock: Buy or Sell?! New Novo Nordisk Analysis from June 7 delivers the answer:
The latest Novo Nordisk figures speak for themselves: Urgent action needed for Novo Nordisk investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from June 7.
Novo Nordisk: Buy or sell? Read more here...
